News – Page 440 – Endpoints News

Amicus execs get back up smiling after being scuffed again by latest setback

3 years ago

Changes afoot at GSK; The first victim of IRA?; As work halts, families behind gene therapy seek control; and more

3 years ago

Citing too many data confounders, FDA adcomm unanimously votes against Y-mAbs' drug for rare brain cancer

3 years ago

Paul Hudson predicts delayed impact on Sanofi from Biden's IRA, as Dupixent beats last quarter's sales

3 years ago

Updated: A shortage of amoxicillin is now being reported by several manufacturers

3 years ago

EMA limits use of JAK inhibitors for at-risk groups in wake of safety concerns

3 years ago

AbbVie preps for an onslaught of Humira biosimilars in 2023, with Skyrizi and Rinvoq to fill the gap for now

3 years ago

Gilead finds 'critical holes' in the government's HIV patent case against it

3 years ago

FDA loosens marketing rules for authorized Covid drugs, but will it move the needle?

3 years ago

Curia breaks ground on $100M expansion project in New Mexico

3 years ago

NIH to study Pfizer's Paxlovid in long Covid as demand — and infections — continue to fall

3 years ago

In final pivot from cancer to rare disease, Agios offloads its share of Tibsovo royalties for $131M

3 years ago

After months of back and forth, Mereo and its biggest stockholder reach truce, replace board members

3 years ago

Penny stock forges ahead with an NDA for Duchenne treatment, seeking priority review

3 years ago

Taking on Big Pharma rivals, biotech startup unveils first-in-human data on ROS1 drug

3 years ago

Blackstone invests $50M in PTC, lines up $1B loan to support dealmaking

3 years ago

As 'lower than projected' data send it back to the drawing board, Sanofi takes $1.6B hit on IL-2

3 years ago

Two Aurinia execs are out — and CRISPR’s operations chief isn't far behind; Biogen MS leader jumps to Eli Lilly ...

3 years ago

Seagen touts progress for Padcev and Tukysa as it continues CEO search

3 years ago

Gilead's $1.7B hep D drug just ran into a roadblock at the FDA

3 years ago

Bristol Myers expands cancer survivor campaign with actor and spokesperson Sterling K. Brown

3 years ago

FDA raises efficacy concerns with Y-mAbs' potential therapy for pediatric neuroblastoma ahead of ODAC meeting

3 years ago

Merck CEO Rob Davis has business development on the brain as he builds 'pipeline of the future'

3 years ago

In next step of opioid saga, McKinsey reaches proposed agreement with school districts and local governments

3 years ago

First page Previous page 437 438 439440441 442 443 Next page Last page